You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,258,778


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,258,778
Title: Methods for accelerating bone and cartilage growth and repair
Abstract:The present invention provides improved methods, kits, and compositions for enhancing bone, cartilage and cartilage repair, bone and prosthesis implantation, and attachment and fixation of cartilage and cartilage to bone or other tissues, and chondrocyte proliferation comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT.sub.2 type 2 receptor agonists.
Inventor(s): Rodgers; Kathleen E. (Long Beach, CA), DiZerega; Gere S. (Pasedena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Application Number:09/352,191
Patent Claims:1. A method for enhancing bone repair in a mammal, comprising the administration of an amount effective for enhancing bone repair in the mammal of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.2 is selected from Arg, Lys, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr;

excluding sequences including R.sup.4 as a terminal Tyr group, or is absent.

2. The method of claim 1 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

3. The method of claim 1 further comprising administration of an amount effective for enhancing bone repair in the mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone.

4. An improved method for bone and prosthesis implantation in a mammal, comprising the administration of an amount effective for enhancing bone and prosthesis implantation in the mammal of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2, and Suc

R.sup.2 is selected from Arg, Lys, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser; homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr;

excluding sequences including R.sup.4 as a terminal Tyr group, or is absent.

5. The method of claim 4 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

6. The method of claim 4 further comprising administration of an amount effective for enhancing bone and prosthesis implantation in the mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone.

7. A kit for enhancing bone repair in a mammal, comprising:

(a) administering an amount effective for enhancing bone repair in the mammal of at least one active agent comprising a sequence comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.1 is selected from Arg, Lys, Ala, Om, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; excluding sequences including R.sup.4 as a terminal Tyr group, or is absent; and

(b) instructions for using the amount effective of active agent to enhance bone repair in a mammal.

8. The kit of claim 7 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

9. The kit of claim 7 further comprising an amount effective for enhancing bone repair in the mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone.

10. The kit of claim 7 further comprising a means for delivery of the active agent.

11. A method for enhancing cartilage repair in a mammal, comprising the administration of an amount effective to enhance cartilage repair to the mammal of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.2 is selected from Arg, Lys, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr;

excluding sequences including R.sup.4 as a terminal Tyr group, or is absent.

12. The method of claim 11 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

13. An improved method for attachment and fixation of cartilage implants to bone or other tissue in a mammal, comprising the administration of an amount effective for attaching and fixing cartilage implants to bone or other tissue in a mammal of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.2 is selected from Arg, Lys, Ala, Om, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr;

excluding sequences including R.sup.4 as a terminal Tyr group, or is absent.

14. The method of claim 13 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

15. An improved medium for the culture of chondrocytes wherein the improvement comprises contacting the cells with an amount effective to accelerate proliferation of chondrocytes of at least one active agent comprising a sequence of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

wherein R.sup.1 is selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.2 is selected from Arg, Lys, Ala, Orn, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr,

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is selected from the group consisting of His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is selected from the group consisting of Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr; excluding sequences including R.sup.4 as a terminal Tyr group, or is absent.

16. The improved chemically defined medium of claim 15 wherein the active agent comprises an amino acid sequence selected from the group consisting of angiotensinogen, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

17. A method for enhancing bone repair in a mammal, comprising the administration of an amount effective for enhancing bone repair in the mammal of at least one active agent of the formula

Asp-Arg-R1-R2-Ile-His-Pro-R2, wherein

R1 is selected from the group consisting of Ile, Pro, Ala, Val, Leu, and norLeu;

R2 is selected from Tyr and Tyr(PO.sub.3).sub.2 ; and

R3 is Phe, or is absent.

18. The method of claim 17 wherein the active agent comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO: 33, SEQ ID NO:41, and SEQ ID NO: 45.

19. The method of claim 17 further comprising the administration of an amount effective for enhancing bone repair in the mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone.

20. An improved method for bone and prosthesis implantation in a mammal, comprising the administration of an amount effective for enhancing bone and prosthesis implantation to the mammal of at least one active agent of the formula

Asp-Arg-R1I-2-Ile-His-Pro-R2, wherein

R1 is selected from the group consisting of Ile, Pro, Ala, Val, Leu, and norLeu;

R2 is selected from Tyr and Tyr(PO3).sub.2 ; and

R3 is Phe, or is absent.

21. The method of claim 20 wherein the active agent comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:31, SEQ ID NO:32,SEQ ID NO:33,SEQ ID NO:41, and SEQ ID NO:45.

22. The method of claim 20 further comprising the administration of an amount effective for enhancing bone repair in the mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone.

23. A method for enhancing cartilage repair in a mammal, comprising the administration of an amount effective to enhance cartilage repair to the mammal of at least one active agent of the formula

R1-R2-R3-R4-R5-His-Pro-R6, wherein

R1 is selected from the group consisting of Hydrogen, Gly, and Asp;

R2 is selected from the group consisting of Arg, Citron, or Ornithine;

R3 is selected from the group consisting of Val, Ile, Ala, Leu, and norLeu, or Pro;

R4 is selected from Tyr, Tyr(PO.sub.3).sub.2, and Ala;

R5 is selected from the group consisting of Ile, Ala, Val, Leu, and norLeu; and

R6 is Phe, Ile, or is absent.

24. An improved method for attachment and fixation of cartilage implants to bone or other tissue in a mammal, comprising the administration of an amount effective for attaching and fixing cartilage implants to bone or other tissue in a mammal of at least one active agent of the formula

R1-R2-R3-R4-R5-His-Pro-R6, wherein

R1 is selected from the group consisting of Hydrogen, Gly, and Asp;

R2 is selected from the group consisting of Arg, Citron, or Ornithine;

R3 is selected from the group consisting of Val, Ile, Ala, Leu, and norLeu, or Pro;

R4 is selected from Tyr, Tyr(PO.sub.3).sub.2, and Ala;

R5 is selected from the group consisting of Ile, Ala, Val, Leu, and norLeu; and

R6 is Phe, Ile, or is absent.

25. A pharmaceutical composition comprising

(a) an amount effective to enhance bone repair or bone and prosthesis implantation in a mammal of at least one active agent comprising a sequence of the formula

Asp-Arg-R1-R2-Ile-His-Pro-R2, wherein

R1 is selected from the group consisting of Ile, Pro, Ala, Val, Leu, and norLeu;

R2 is selected from Tyr and Tyr(PO.sub.3).sub.2 ; and

R3 is Phe, or is absent; and

(b) an amount effective to enhance bone repair or bone and prosthesis implantation in a mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone; and

(c) a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising

(a) an amount effective to enhance bone repair or bone and prosthesis implantation in a mammal of at least one active agent comprising a sequence consisting of at least three contiguous amino acids of groups R.sup.1 -R.sup.8 in the sequence of general formula I

in which R.sup.1 and R.sup.2 together form a group of formula

wherein X is H or a one to three peptide group, or is absent,

R.sup.A is suitably selected from H, Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me.sup.2 Gly, Pro, Bet, Glu(NH.sub.2), Gly, Asp(NH.sub.2) and Suc,

R.sup.B is suitably selected from Arg, Lys, Ala, Om, Citron, Ser(Ac), Sar, D-Arg and D-Lys;

R.sup.3 is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;

R.sup.4 is selected from the group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ala, Ser, homoSer and azaTyr;

R.sup.5 is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R.sup.6 is His, Arg or 6-NH.sub.2 -Phe;

R.sup.7 is Pro or Ala; and

R.sup.8 is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a terminal Tyr group, or is absent;

(b) an amount effective to enhance bone repair or bone and prosthesis implantation in a mammal of at least one compound selected from bone morphogenic protein-2, bone morphogenic protein-4, bone morphogenic protein-6, bone morphogenic protein-7, transforming growth factor-beta, insulin-like growth factor, and parathyroid hormone; and

(c) a pharmaceutically acceptable carrier.

27. The method of any one of claims 1, 4, 15 or 19 wherein the active agent comprises at least four contiguous amino acids of general formula I.

28. The method of any one of claims 1, 4, 15 or 19 wherein the active agent comprises at least five contiguous amino acids of general formula I.

29. The method of any one of claims 1, 4, 15 or 19 wherein the active agent comprises at least six contiguous amino acids of general formula I.

30. The method of any one of claims 1, 4, 15 or 19 wherein the active agent comprises at least seven contiguous amino acids of general formula I.

31. The method of any one of claims 1, 4, 15 or 19 wherein the active agent consists of at least three contiguous amino acids of general formula I.

32. The method of any one of claims 1, 4, 11 or 13 wherein the active agent consists of at least four contiguous amino acids of general formula I.

33. The method of any one of claims 1, 4, 11 or 13 wherein the active agent consists of at least five contiguous amino acids of general formula I.

34. The method of any one of claims 1, 4, 11 or 13 wherein the active agent consists of at least six contiguous amino acids of general formula I.

35. The method of any one of claims 1, 4, 11 or 13 wherein the active agent consists of at least seven contiguous amino acids of general formula I.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.